2022 var ett starkt år trots utmaningar och marginalpress Nettoomsättningen steg med 11% till 261 mk...
Redeye takes a positive view of today’s news, where Westpay has entered an agreement that will enhan...
Fortsatt hög uthyrningsgrad och ökade driftöverskott Hyresintäkter i kvartalet uppgick till 8,5 mEUR...
Redeye adjusts our growth assumptions for 2023e and beyond, the Q4 report increases our conviction i...
Reached '22 guidance, but disappointing '23 guidance Proposed DPS of DKK 4.
Q4'22 pre-tax profit +2% vs. ABGSCe Positive signs on trading income and costs '23e-'24e 6% div.
CirChem publicerade den 7 februari bolagets delårsrapport för årets fjärde kvartal.
Q4 15% below us on EBITA, but Medical beat expectations Integrated the main driver of estimate downg...
Redeye comments on Annexin’s Q4 report, which came in as expected, and largely reiterate our view of...
Q4'22 pre-tax profit +2% vs ABGSC 2022 ended with a rebound in trading income Proposed DPS at DKK 0.
Raute reports Q4 results on Feb 14. There’s still haze around revenue and margins going forward, but...
Redeye will likely make minor forecast adjustments following Bredband2’s Q4 2022 report.
Redeye gives a comment on Xavi Solutions Q4 2022 report that was revealed earlier today.
Sales SEK 438m, -2% vs. ABGSCe Adj. EBITA SEK 54m, 3% vs ABGSCe On unrevised ests, share trading at ...
33% org growth, but 27% EBIT miss due to OEM+VIP+FX 26% EBIT CAGR 2022-2025e on 30% margins 25-15x E...
Redeye is positively surprised by the better-than-expected Q4 report this morning.
Redeye leaves its comments on Respiratorius following its Q3 report (split calendar year).
Q4 NOI +69% y-o-y, +4% vs ABGSCe Net LTV at 50.7% (95% (Eastnine currently at 96.
Redeye sees a Q4 report that was uneventful as expected.
Redeyes view on the Q4 report. The report was weak, and the challenges continue to affect the compan...
